首页
登录
职称英语
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administ
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administ
游客
2023-12-27
22
管理
问题
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administration(FDA)advisory panel’s recommendation earlier this year that Vioxx and its cousins Bextra and Celebrex(all medicines known as Cox-2 inhibitors)should remain on the market, despite evidence they increase heart disease risk in some people. The panelists reached their decision after weighing all the data and concluding the benefits of these pain-relieving drugs outweighed the risks.
Specifically, these scientists acknowledged that, for some patients, these prescription drugs were uniquely effective in reducing pain from arthritis and other causes. For others—concerned about ulcers associated with aspirin and other OTC analgesics—the Cox-2 inhibitors offered the advantage of minimizing potentially serious effects of stomach irritation.
Now is an appropriate time for everyone to take a fresh look at the benefit-risk equation for Vioxx and the other Cox-2 inhibitors.
The risks— increased risk of heart disease in some who use the drugs—have been well publicized. Much less publicity has been given to a spectrum of real and potential benefits that go way beyond reduced risk of stomach irritation. These little-discussed benefits would have been lost, perhaps permanently-had Vioxx, Bextra and Celebrex been driven from shelves in pursuit of perfect safety, an unattainable goal.
For example, there is substantial evidence Cox-2 inhibitors can reduce development of colon polyps, which may become colon canceL Indeed. Celebrex is FDA-approved for those genetically prone to colon cancer. Ironically, the 2004 study that revealed the elevated heart attack risk of Vioxx was primarily designed to further establish the drug’s effectiveness in protecting against colon cancer. And while the results of that interrupted trial have not yet been published, there is good reason to believe they will confirm the protective effects against colon cancer established in research over the last 10 years.
At the time of its withdrawal from the market last fall, studies of Vioxx as well as the other Cox-2 drugs suggest that they had other anti-cancer properties as well, possibly reducing the risk of malignancies of a number of sites, including the lung and esophagus.
Had these drugs been dismissed, their untapped promise for prevention would have evaporated well before it was evaluated and applied to save lives. Fortunately, cooler and wiser heads prevailed. [br] The word "unattainable" underlined in Paragraph 4 is closest in meaning to______.
选项
A、unrealizable
B、undoable
C、unachievable
D、impossible
答案
A
解析
根据文中第四段的内容“in pursuit of perfect safety,an unattainable goal”可知,为了追求完美的安全,也就是一个无法完成的目标。选项中的A项为“无法实现的”符合文意。B项“不能做的”,C项“不能实现的",D项“不可能的”,这三项均不符合题意。
转载请注明原文地址:https://tihaiku.com/zcyy/3308692.html
相关试题推荐
Iamdelightedthatweareonceagaincelebratingtheachievementsofourcol
Iamdelightedtobeheretodayatthisschoolofhighachievers.Firstofa
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
Washington:TheBushadministrationhas【C1】______forthefirsttimethatit
随机试题
Injuniorhighschool,oneofmyclassmateshadaTVaddiction—backbeforei
[originaltext]Ifyou’vebeenoncampusforverylong,I’mcertainthatyou’v
常用的寿命周期成本分析方法包括()。A:费用效率法 B:模型估算法 C:固
与四川省有关的世界遗产项目()A.中国大运河 B.九寨沟 C.黄龙 D.三
根据以下资料 2011年我国网上购物保持高速发展态势,全年网购总额达到8090
(____)变压器抽真空注油时,应接通变压器本体与开关油室旁通管,保持开关油室与
根据下列统计资料回答问题。 2008年,专任教师比重最高的是()。 A.教
(2017年5月)在绩效改进指导过程中,考评者与被考评者讨论的核心问题是()A
在下列说法中,正确的是A.国家机关工作人员利用职权非法拘禁他人的,应以非法拘禁罪
铸造钴铬合金卡环臂端进入倒凹的深度为( )。A.0.25mm B.0.5mm
最新回复
(
0
)